Clinical trials
Atrophy clinical trials
Below are recruiting atrophy clinical trials, each written for real people, not researchers. We’re tracking 269 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age - NCT06647641Recruiting
Genetics study for PSP, CBS, MSA, and related conditions
This study looks at genetic factors in people with PSP, CBS, MSA, or similar brain conditions, and also in their family members. It involves genetic testing to learn more about these diseases and may help find new treatments.
Boston, MassachusettsAges 35 years+ - NCT07024667Recruiting
Laser treatment study for vaginal atrophy symptoms
This trial tests a carbon dioxide laser (FemiLift) to see if it can help women with vaginal dryness, burning, itching, or pain during sex caused by menopause. It aims to improve symptoms without hormones.
HaderaAges 45–75 - NCT06828640Recruiting
Vaginal dilator for menopause-related dryness
This trial tests whether using a vaginal dilator (a gentle, cone-shaped device) can help with vaginal dryness, burning, or pain caused by menopause or breast cancer treatments. It adds to your usual care.
Brussels, Brussels CapitalAges 18–85 - NCT07047144RecruitingPhase 2
Apitegromab for infants with SMA under 2 years old
This study tests a new medicine called apitegromab for babies under 2 years old with spinal muscular atrophy (SMA). It looks at whether the drug can help with muscle strength and reaching motor milestones like sitting or rolling.
Phoenix, ArizonaAges Up to 2 years - NCT06970106RecruitingPhase 1/Phase 2
Study of PYC-001 eye injections for people with a type of inherited optic nerve disease
This trial tests a new medicine called PYC-001, given as an injection into the eye, for people with a specific genetic form of vision loss called autosomal dominant optic atrophy (ADOA). It aims to see if the treatment is safe and could help protect or improve vision.
Sydney, New South WalesAges 18 years+ - NCT06562283Recruiting
Reproducibility of a fatigue test for spinal muscular atrophy
This study checks how consistent a fatigue test is for people with spinal muscular atrophy (SMA). It helps doctors better understand fatigue in SMA and may improve future care.
Saint-Etienne, FranceAges 6 years+ - NCT06765733RecruitingEarly Phase 1
Testing Aleeto for multiple system atrophy (MSA)
This trial tests a new treatment called Aleeto for people with a specific type of multiple system atrophy (MSA-P) who haven't responded well to standard Parkinson's medications. The goal is to see if Aleeto is safe and might help improve symptoms.
Beijing, Beijing MunicipalityAges 30–75 - NCT06977269Recruiting
Brain stimulation safety study for spinal muscular atrophy
This trial tests whether a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) is safe and tolerable for people with spinal muscular atrophy (SMA). It may help improve muscle function by activating low motor neurons.
Kharkiv, Kharkiv OblastAges 12 years+ - NCT07287982RecruitingPhase 2
ARGX-119 for children with SMA who can walk
This study tests a new medicine called ARGX-119 in children with SMA. It is given through an IV and aims to help kids who can already walk get stronger and stay healthy.
Little Rock, ArkansasAges 5–17 - NCT07174687RecruitingPhase 2
SGLT2 inhibitor for geographic atrophy
This study tests an SGLT2 inhibitor (dapagliflozin) as a possible treatment for geographic atrophy, a progressive form of dry age-related macular degeneration that causes vision loss. It is for people who meet specific eye and health criteria.
St Louis, MissouriAges 50 years+ - NCT07554924RecruitingPhase 1/Phase 2
Gene therapy for newly diagnosed spinal muscular atrophy type I infants
This study tests SKG0201, a new gene therapy designed to treat spinal muscular atrophy type I (SMA type I), a rare genetic condition affecting muscle strength. The trial enrolls very young infants diagnosed with SMA type I to see if the treatment is safe and helps improve muscle function.
Beijing, Beijing MunicipalityAges Up to 6 months - NCT06555419RecruitingPhase 1
Nusinersen dosing study via flexible spinal catheter
This trial investigates how the drug nusinersen (Spinraza) enters the body when given through a small, flexible tube placed in the lower back (ThecaFlex DRx system). It aims to learn how the drug is processed in adults and children with spinal muscular atrophy, which could help make dosing more convenient.
Orange, CaliforniaAges 3 years+ - NCT07441642RecruitingPhase 2
Study of FWY003 for geographic atrophy in age-related macular degeneration
This trial tests an investigational drug FWY003 against a placebo to see if it can slow or stop the progression of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss.
Huntington Beach, CaliforniaAges 50 years+ - NCT07221669RecruitingPhase 3
Pre-symptomatic salanersen study for babies with SMA
This trial tests if the drug salanersen can help movement and is safe when given to babies diagnosed with spinal muscular atrophy before they show symptoms. It's for very young infants with specific genetic types of SMA.
Chicago, IllinoisAges birth–1 month - NCT05866419Recruiting
Study of a port and catheter system for spinal muscular atrophy
This study tests a new device called the ThecaFlex DRx System, which is a small port and catheter placed under the skin to deliver Spinraza directly into spinal fluid—instead of needing repeated spinal taps. The device aims to make receiving medication easier and safer for people with SMA.
Phoenix, ArizonaAges 3 years+ - NCT06659549RecruitingPhase 2
Eye drop treatment for advanced dry AMD with geographic atrophy
This trial tests a daily eye drop (GAL-101) to see if it can slow the growth of geographic atrophy lesions in people with dry age-related macular degeneration (AMD) when the center of the macula is not yet involved.
Beverly Hills, CaliforniaAges 55 years+ - NCT06541704RecruitingPhase 3
Study of pozelimab with cemdisiran for geographic atrophy
This trial tests a combination of two study drugs (pozelimab and cemdisiran) given as a shot under the skin to slow the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes blind spots in central vision.
Chandler, ArizonaAges 50–85 - NCT07444450RecruitingPhase 3
Study of salanersen for babies with SMA previously treated with gene therapy
This study tests a new medicine called salanersen in babies who have already received gene therapy for SMA. It aims to see if adding salanersen is safe and effective.
Flower Mound, TexasAges birth–7 months - NCT06765980RecruitingPhase 1/Phase 2
Study of KRIYA-825 for geographic atrophy in age-related macular degeneration
This trial tests an experimental drug called KRIYA-825 (also known as VV-14295) for people with geographic atrophy, a late stage of dry age-related macular degeneration that causes vision loss. The study aims to see if the treatment is safe and can help slow the progression of the disease.
Erie, PennsylvaniaAges 55–80 - NCT07197866RecruitingPhase 2
Extension study of TEV-56286 for multiple system atrophy
This trial tests whether the drug TEV-56286 continues to work for multiple system atrophy (a rare brain disorder). It is for people who already completed a previous study of the same drug.
La Jolla, CaliforniaAges 30 years+ - NCT06019637Recruiting
Long-term safety study of Zolgensma for spinal muscular atrophy
This study follows the long-term safety of Zolgensma gene therapy in Brazilian children with spinal muscular atrophy (SMA). It helps doctors understand how safe the treatment is over time.
Curitiba, ParanáAges birth–100 years - NCT06363942Recruiting
Video exercise program for fall prevention in frail older adults
This trial tests a personalized video-based exercise program to help older adults who are frail or pre-frail prevent falls. It may be a good fit if you are relatively healthy aside from frailty concerns.
Montreal, QuebecAges 70 years+ - NCT07700095Recruiting
Comparing two ways to rebuild jawbone for dental implants
This trial tests two ways to rebuild bone in the back lower jaw using special barriers (custom 3D zirconia or titanium mesh) to support a dental implant. It may help if you have severe bone loss and want an implant.
Kafr ElsheikhAges 20–50
Hear when a new Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for atrophy?
- Yes. Clin2 currently lists 269 recruiting atrophy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a atrophy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a atrophy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.